Im up early for the gym, so I grab a big cup of black coffee (Dunkin K-Cup forever!) and head out the door
Portion-Controlled for Changing Appetite Our meals range from 300-600 calories depending on the plan you choose
It reads pathway-level markers such as MC4R, GLP1R, and FTO that describe baseline metabolic biology information that stays the same regardless of how any medication is ultimately paid for
Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation
In contrast, the expression of GLP-1 mRNA in the colon tissues of mice in the model group decreased, and the content of GLP-1 in serum decreased
I joined a Discord that I found from Reddit of peptide enthusiasts
